Hundreds of pharmaceutical companies publish annual reports

Source: according to the data of tonghuashun on March 2, 2018 in Securities Daily, as of March 1, 194 listed biomedical companies in a share issued performance forecast 157 listed companies issued performance bulletins According to the data, 147 listed companies are expected to achieve year-on-year growth in 2017, of which 35 are expected to double their performance last year In addition, 47 listed companies' performance declined to varying degrees, among which 24 biomedical companies' performance declined by more than 50% In an interview with the Securities Daily, Shi lichen, founder of the third-party medical service platform mesconway, said that in 2017, the performance of pharmaceutical enterprises was average In 2018, with the full implementation of the two vote system, especially under the influence of multiple combination boxing policies such as medical insurance fee control, drug bidding, and second bargaining, the drug price is expected to further reduce, and the use of non therapeutic drugs will be further improved The business performance will be even worse if it is limited In addition, an industry person told reporters that in the future, the phenomenon of "double ice and fire" in the pharmaceutical industry will be more obvious High quality enterprises will be better and better, while poor enterprises will be phased out The performance growth of 114 pharmaceutical companies is more than 30% affected by policies, and the performance differentiation has become a major feature of the overall performance of biopharmaceutical companies in recent years According to the data, 114 listed biomedical companies have achieved more than 30% performance growth Four listed companies, Beirui gene, Tianmu pharmaceutical, Furen pharmaceutical and Zhifei biology, are expected to increase their performance by more than 1000% In addition, many listed companies, such as Laimei pharmaceutical, Yabao pharmaceutical, Chengzhi Co., Ltd., Beilu pharmaceutical and Lizhu group, are expected to increase their performance by more than 100% Many listed companies, such as Haiwang biology, Yifan medicine, Jincheng medicine, guangyuyuan, Yaoshi technology and meinian health, are expected to increase their performance by more than 50% Among the above 114 listed companies, there are 17 chemical API companies, 23 chemical preparation companies, 16 biological products companies, 13 medical service companies, 17 medical device companies, 7 pharmaceutical commercial companies and 21 traditional Chinese medicine companies Among the listed companies with declining performance, Boji pharmaceutical, Jiuan medical, Watson biology, Jiaying pharmaceutical, Qianshan pharmaceutical and Zhongyuan Xiehe expect a 100% decline in performance Taiji group, Lexin medical, Guonong science and technology, Haihong holding, qidiguhan and other listed companies are expected to see a 50% decline in performance In 2017, due to the impact of medical insurance fee control and drug bidding, especially the limited use of auxiliary drugs, the performance of several listed companies was affected According to the reporter, some products, including HongRi pharmaceutical, Yuheng pharmaceutical and other pharmaceutical enterprises, were affected by the pressure of medical insurance and fee control It is worth mentioning that the change of policy also leads to a new round of value reconstruction in the pharmaceutical market Enterprises with innovative R & D capabilities and rich product lines are sought after by the market A number of pharmaceutical companies said that when responding to market changes, enterprises with rising marketing costs continued to carry out marketing reform and also increased cost input For example, Yuheng pharmaceutical expects net profit attributable to shareholders of listed companies to decline by 56% in 2017 Yuheng pharmaceutical said that during the reporting period, the company's operating profit, total profit, net profit attributable to the listed company, and basic earnings per share decreased significantly, mainly due to the impact of the two vote system policy, the company's adjustment of sales mode, and the sharp rise in sales expenses Longshenrongfa introduced in the 2017 performance express that during the reporting period, the company's operating revenue was 269.587 million yuan, basically the same as that of the same period in 2016; the net profit attributable to shareholders of the listed company was 16.4964 million yuan, down 65.09% from that of the same period in 2016 One of the reasons for the change in performance is that during the reporting period, the pharmaceutical market deepened its reform, the company overcame the influence of comprehensive factors such as the proportion control of hospital drugs, the control of medical insurance fees, the second price negotiation of drug bidding, increased the construction of marketing network, actively carried out market promotion, continued to promote and implement the development goals, and the sales expenses increased by more than 20 million yuan compared with the same period in 2016 The increase in sales costs also comes from Longjin pharmaceutical Longjin pharmaceutical expects that in 2017, the company's operating revenue will be 304.4477 million yuan, an increase of 36.14% year on year; the net profit attributable to shareholders of listed companies will be 35.0373 million yuan, a decrease of 61.51% year on year As for the performance decline, Longjin pharmaceutical explained that in 2017, in response to the new round of bid winning regions' requirements for distributors, the company accelerated the transformation from refined marketing to in-depth distribution nationwide However, in the early stage of transformation, the sales expenses increased significantly, which had a negative impact on the company's profits At the same time, the company's investment in the secondary development of existing products and new drug research and development continued to increase The development expenses led to the increase of management expenses, which led to a significant decline in the net profit attributable to shareholders of listed companies compared with the same period in 2016 Original title: performance of pharmaceutical industry: limited use of complementary drugs in the double hot days, leading to performance decline of several pharmaceutical enterprises